Palatin Technologies Inc

NYSE American:PTNUnited States

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.

Contact Information

Headquarters

4B Cedar Brook DriveCRANBURY, NJ, United States 08512

Phone

609-495-2200

Fax

609-495-2202

Executives

Independent Chairman of the Board

John Prendergast

President, Chief Executive Officer, Director

Carl Spana

Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary

Stephen Wills

Independent Director

Robert Deveer

Independent Director

Alan Dunton